Ultragenyx Pharmaceutical, the Novato-based developer of treatments for ultra-rare diseases has announced the addition of Lars Ekman, M.D., Ph.D. to the company’s Board of Directors. Dr. Ekman, Executive Partner at Sofinnova Ventures, will serve as an independent director to Ultragenyx. Seperately, Ultragenyx announced that they have entered into three-year sponsored research and option agreements to collaborate with Saint Louis University’s Center for World Health and Medicine (CWHM) on the development of small molecule therapeutics for the potential treatment of Facioscapulohumeral Muscular Dystrophy (FSHD). Emil D. Kakkis, Ultragenyx CEO, notes, “SLU has already made significant progress in the area of FSHD research, and we are excited to begin a robust collaboration to bring forward what we hope will be the first treatment for this debilitating and progressive disease.”
For more information visit the Ultragenyx website.